137 related articles for article (PubMed ID: 16985100)
1. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
Karjalainen MJ; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2006 Dec; 34(12):2091-6. PubMed ID: 16985100
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.
Karjalainen MJ; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):157-65. PubMed ID: 18816299
[TBL] [Abstract][Full Text] [Related]
3. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
Backman JT; Karjalainen MJ; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Sep; 62(3):345-57. PubMed ID: 16934051
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
Lu P; Schrag ML; Slaughter DE; Raab CE; Shou M; Rodrigues AD
Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767
[TBL] [Abstract][Full Text] [Related]
5. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
[TBL] [Abstract][Full Text] [Related]
6. Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine.
Agúndez JA; Gallardo L; Martínez C; Gervasini G; Benítez J
Pharmacogenetics; 1998 Jun; 8(3):251-8. PubMed ID: 9682270
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.
Alvarez-Diez TM; Zheng J
Chem Res Toxicol; 2004 Feb; 17(2):150-7. PubMed ID: 14967002
[TBL] [Abstract][Full Text] [Related]
8. Effect of dimethyl sulfoxide on in vitro cytochrome P4501A2 mediated phenacetin O-deethylation in human liver microsomes.
Nirogi R; Kandikere V; Bhyrapuneni G; Ponnamaneni RK; Palacharla Rc; Manoharan A
Drug Metab Dispos; 2011 Nov; 39(11):2162-4. PubMed ID: 21825116
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions.
Thelingwani RS; Zvada SP; Dolgos H; Ungell AL; Masimirembwa CM
Drug Metab Dispos; 2009 Jun; 37(6):1286-94. PubMed ID: 19299526
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 1999 Dec; 27(12):1519-22. PubMed ID: 10627170
[No Abstract] [Full Text] [Related]
11. Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats.
Zhu Q; Liao J; Xie L; Wang GJ; Liu XD
Xenobiotica; 2009 Apr; 39(4):293-301. PubMed ID: 19350452
[TBL] [Abstract][Full Text] [Related]
12. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
13. [O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes.
Rodrigues AD; Surber BW; Yao Y; Wong SL; Roberts EM
Drug Metab Dispos; 1997 Sep; 25(9):1097-100. PubMed ID: 9311627
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibitory effect of luotonin A on human CYP1A.
Jahng Y; Kwon OK; Lee S
Arch Pharm Res; 2012 Dec; 35(12):2199-203. PubMed ID: 23263815
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
[TBL] [Abstract][Full Text] [Related]
16. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones.
Hu M; Krausz K; Chen J; Ge X; Li J; Gelboin HL; Gonzalez FJ
Drug Metab Dispos; 2003 Jul; 31(7):924-31. PubMed ID: 12814970
[TBL] [Abstract][Full Text] [Related]
17. Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates.
Wang X; Lee WY; Or PM; Yeung JH
Phytomedicine; 2009 Aug; 16(8):712-25. PubMed ID: 19403289
[TBL] [Abstract][Full Text] [Related]
18. Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
Wattanachai N; Tassaneeyakul W; Rowland A; Elliot DJ; Bowalgaha K; Knights KM; Miners JO
Drug Metab Dispos; 2012 May; 40(5):982-9. PubMed ID: 22331994
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe.
Bachmann K; White D; Jauregui L; Schwartz JI; Agrawal NG; Mazenko R; Larson PJ; Porras AG
J Clin Pharmacol; 2003 Oct; 43(10):1082-90. PubMed ID: 14517190
[TBL] [Abstract][Full Text] [Related]
20. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
